相关实验视频

Updated: Jun 2, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

尿路细胞癌的基于免疫组织化学的分子亚型从化疗化学疗法中获得了不同的生存益处

Csilla Olah¹, Oleksandr Shmorhun², Gilbert Georg Klamminger²

¹Department of Urology, University of Duisburg-Essen, Essen, Germany.

The journal of pathology. Clinical research

|January 16, 2025

概括

肌肉侵入性膀癌 (MIBC) 的基因组不稳定 (GU) 亚型显示,辅助化疗 (AC) 的生存率有所改善. 瘤异质性会影响治疗的有效性,特别是在初级瘤和淋巴结转移之间.

科学领域:

在瘤学瘤学.
翻译研究是翻译研究.
分子病理学分子病理学

背景情况:

肌肉侵入性膀癌 (MIBC) 呈现出不同的分子亚型,具有不同的敏感度.
主要来自转录学的现有数据缺乏可比性;蛋白质表达提供了更标准化的方法.
了解瘤异质性对于预测治疗反应至关重要.

研究的目的:

使用隆德分类学 (基于蛋白质表达) 确定MIBC分子亚型的敏感性.
评估原发性瘤内部以及原发性和转移性部位之间的瘤异质性.
在不同的治疗环境中,将分子亚型与总生存率 (OS) 相关联起来.

主要方法:

从199名化疗先验MIBC患者的组织微阵列 (1508个核心) 上利用了13个标记物的免疫组织化学.
将患者分为三个队伍:激进囊切除术,辅助化疗 (AC) 和性白金治疗.
分析了作为主要终点的整体存活率 (OS),评估内和位间异质性.

主要成果:

基因组不稳定 (GU) 亚型与激进囊切除术相比,通过AC显著改善了与AC相比的生存状况 (HR:0.395,p=0.005).
在基底/状 (Ba/Sq) 亚型中没有观察到显著的OS差异.
在19%的病例中发现了内瘤异质性,主要瘤和淋巴结 (LN) 转移之间的异质性更高.

结论:

基于免疫组织化学的隆德分类学亚型在主要MIBC瘤中基本稳定.
在 OS方面,GU亚型从辅助化疗 (AC) 中获益最多.
主要和转移部位之间的显著瘤异质性可能会损害治疗的有效性.

关键词:

隆德分类学隆德分类学膀癌:膀癌是一种癌症.化疗化疗是一种化学疗法.西斯普拉丁 (cisplatin) 是一种制剂.免疫组织化学免疫组织化学分子亚型分类分子亚型分类

更多相关视频

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...